1221485-92-2

Upstream product

• 23788-74-1 (R)-2,2-dimethyl-1,3-dioxolane-4-ylmethyl p-toluenesulfonate 
• 1221486-55-0 2-[2-(3-chlorophenyl)-vinyl]-4-methoxybenzoic acid 
• 1221486-58-3 2-chloro-8-hydroxy-10,11-dihydrodibenzo[a,d]cyclohepten-5-one 
• 1221486-57-2 2-chloro-8-methoxy-10,11-dihydrodibenzo[a,d]cyclohepten-5-one 
• 1221486-56-1 2-[2-(3-chlorophenyl)-ethyl]-4-methoxybenzoic acid 
• 1221486-78-7 2-bromomethyl-4-methoxybenzoic acid 
• 6245-57-4 4-methoxy-2-methylbenzoic acid 
• 587-04-2 m-Chlorobenzaldehyde 
• 1221486-59-4 S-2-chloro-8-(2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-10,11-dihydro-dibenzo-[a,d]cyclohepten-5-one 
• 367-25-9 2,4-difluorophenylamine 

Downstream Products

• 1221485-93-3 R-2-(2,4-difluorophenylamino)-8-(2,3-dihydroxypropoxy)-10,11-dihydrodibenzo-[a,d]cyclohepten-5-one 

Relevant academic research and scientific papers

Design, Synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase

Synthesis, biological testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivatives as p38 MAP kinase inhibitors are described. Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of th

DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS

The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1β and/or TNF-α. The